21 research outputs found
Tumor characterization and stratification by integrated molecular profiles reveals essential pan-cancer features
Inducing cancer indolence by targeting mitochondrial Complex I is potentiated by blocking macrophage-mediated adaptive responses
Detection of human Papilloma virus DNA in a subset of glioblastoma samples
BACKGROUND: Glioblastoma Multiforme (GBM) is the most common malignant brain tumor in adults, but its aetiology remains unknown. Recent reports have demonstrated the presence of neurotropic viruses in glioma samples, leading to the hypothesis that viral infection could be involved in tumorigenesis. AIM OF THE STUDY: To assess the burden of HPV infection in a cohort of malignant gliomas. MATERIALS AND METHODS: Seventy-one fresh frozen tumour samples of 62 glioblastomas and 9 grade III astrocytomas have been retrospectively analyzed. The presence of HPV genome in tumour DNA was assessed by MY/GP nested PCR. PCR products were sequenced with Sanger technology in order to define the viral genotype involved in the infection. A PCR with genotype-specific primer sets was carried out as confirmation of the infection. RESULTS: Viral DNA was detected after PCR in 8 (11%) cases. According to our previous studies both low- and high risk genotypes were isolated. Sequencing analysis showed that HPV16 genome was present in 4 (50%) infected samples whereas the remaining 4 resulted positive to HPV6. All positive cases were diagnosed as primary glioblastomas, and no positivity was found in lower grade glioma samples. Median overall survival did not significantly differ between HPV-positive and HPV-negative patients. CONCLUSIONS: The presence of HPV in high grade glioma specimens deserves further investigation. The analysis of a large cohort of tumors, along with in vitro studies on glioblastoma cell lines, will allow to better clarify the role of HPV in gliomagenesis and assess its potential use as a prognostic factor
The RET51/FKBP52 complex and its involvement in Parkinson disease.
The tyrosine kinase receptor RET51 is expressed in distinct families of neurons
where it promotes different functions. FKBP52 is an immunophilin with
neuroprotective effects on different kinds of neurons. In this paper, we
demonstrate that RET51 activation by both glial cell line-derived neurotrophic
factor (GDNF) and NGF triggers the formation of RET51/FKBP52 complex. The
substitution of the tyrosine 905 of RET51, a key residue phosphorylated by both
GDNF and NGF, disrupts the RET51/FKBP52 complex. NGF and GDNF have a functional
role in dopaminergic (DA) neurons where RET51 and FKBP52 are expressed with a yet
undefined function. To clarify if RET51/FKBP52 complex should exert its function
in DA neurons, we used an indirect approach by screening the genes encoding for
RET51 and FKBP52 in a group of 30 Parkinson's disease patients. The degeneration
of DA neurons is the main feature of PD, which is associated to a complex
multifactorial aetiology combining environmental, age-related and genetic
factors. We found a compound heterozygous carrying two mutations in RET and
FKBP52 that are sufficient to disrupt the RET51/FKBP52 complex, indicating its
potential role in PD
Evidence of association of human papillomavirus with prognosis worsening in glioblastoma multiforme
Background: Glioblastoma multiforme (GBM) is the most malignant brain tumor in adults, but its etiology still remains unknown. Recently, a role of viruses such as cytomegalovirus and JC virus in gliomagenesis has been suggested. Since human papillomavirus (HPV) is considered the most common oncogenic virus in humans, we evaluated its occurrence in GBM samples.
Material and Methods: Fifty-two formalin-fixed paraffin-embedded primary glioblastoma specimens were retrospectively analyzed. The presence of HPV genome on tumor DNA was assessed by MY/GP nested PCR. Confirmation of HPV detection was obtained by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) with an antibody directed against the L1 capsidic protein. Finally, univariate and multivariate proportional-hazards models were used to compare the risk of death among HPV-positive and HPV-negative patients.
Results: Strikingly, viral DNA was detected after PCR in 12 cases (23%). HPV16 genome was present in 25% infected samples, whereas the remaining samples tested positive for HPV6. CISH confirmed positivity in all infected samples for which enough material was available. Moreover, IHC positivity suggested that production of viral proteins from HPV genome is an ongoing process in GBM cancer cells. Finally an association between HPV infection and a worse prognosis was found in patients upon age stratification with a univariate analysis (HR, 2.10; 95% CI, 1.00–4.44; log-rank P = .045).
Conclusions: HPV infection status may be considered an independent prognostic factor in GBM patients and suggests that prevention may be considered, should HPV be recognized as a causative agent in gliomagenesis
A comprehensive characterization of mitochondrial DNA mutations in glioblastoma multiforme
Glioblastoma multiforme (GBM) is the most malignant brain cancer in adults, with a poor prognosis, whose molecular stratification still represents a challenge in pathology and clinics. On the other hand, mitochondrial DNA (mtDNA) mutations have been found in most tumors as modifiers of the bioenergetics state, albeit in GBM a characterization of the mtDNA status is lacking to date. Here, a characterization of the burden of mtDNA mutations in GBM samples was performed. First, investigation of tumor-specific vs. non tumor-specific mutations was carried out with the MToolBox bioinformatics pipeline by analyzing 45 matched tumor/blood samples, from whole genome or whole exome sequencing datasets obtained from The Cancer Genome Atlas (TCGA) consortium. Additionally, the entire mtDNA sequence was obtained in a dataset of 104 fresh-frozen GBM samples. Mitochondrial mutations with potential pathogenic interest were prioritized based on heteroplasmic fraction, nucleotide variability, and in silico prediction of pathogenicity. A preliminary biochemical analysis of the activity of mitochondrial respiratory complexes was also performed on fresh-frozen GBM samples. Although a high number of mutations was detected, we report that the large majority of them does not pass the prioritization filters. Therefore, a relatively limited burden of pathogenic mutations is indeed carried by GBM, which did not appear to determine a general impairment of the respiratory chain. This article is part of a Directed Issue entitled: Energy Metabolism Disorders and Therapies
Platinum-induced mitochondrial DNA mutations confer lower sensitivity to paclitaxel by impairing tubulin cytoskeletal organization
Development of chemoresistance is a cogent clinical issue in oncology, whereby combination of anticancer drugs is usually preferred also to enhance efficacy. Paclitaxel (PTX), combined with carboplatin, represents the standard first-line chemotherapy for different types of cancers. We here depict a double-edge role of mitochondrial DNA (mtDNA) mutations induced in cancer cells after treatment with platinum. MtDNA mutations were positively selected by PTX, and they determined a decrease in the mitochondrial respiratory function, as well as in proliferative and tumorigenic potential, in terms of migratory and invasive capacity. Moreover, cells bearing mtDNA mutations lacked filamentous tubulin, the main target of PTX, and failed to reorient the Golgi body upon appropriate stimuli. We also show that the bioenergetic and cytoskeletal phenotype were transferred along with mtDNA mutations in transmitochondrial hybrids, and that this also conferred PTX resistance to recipient cells. Overall, our data show that platinum-induced deleterious mtDNA mutations confer resistance to PTX, and confirm what we previously reported in an ovarian cancer patient treated with carboplatin and PTX who developed a quiescent yet resistant tumor mass harboring mtDNA mutations